|Day Low/High||3.31 / 3.47|
|52 Wk Low/High||1.99 / 5.05|
REDWOOD CITY, Calif., April 11, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
The portfolio had a strong start to the June quarter, due in part to the small cap-heavy Russell 2000 leading the market higher.
Last week was a very strong one for many of our positions as the domestic market ended the first quarter on a high note.
During the week we brought Fitbit back into the portfolio and added Digital Turbine to the Bullpen.
Last week was a very good one for the portfolio as nine of our 13 holdings outperformed our benchmark, the Russell 2000.
We initiated one position and exited another during a tough week for small-cap stocks.
REDWOOD CITY, Calif., March 11, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
Is action required for AcelRx Pharmaceuticals and Energy Recovery?
- DSUVIA now available for use in certified medically supervised healthcare settings, with initial shipments to wholesalers completed in the second half of February 2019
We rang the register on part of a high-flying position and added to another on weakness.
With the small-cap heavy Russell 2000 leading the major market index pack last week, we saw a number of pronounced moves higher in the portfolio.
REDWOOD CITY, Calif., Feb.
Another melt-up for the stock market, together with a late-Friday surge was a positive for several portfolio holdings.
We closed our position in Fitbit for a healthy profit and added twice to USA Technologies last week.
We booked hefty wins last week exiting Blue Apron and GE and trimming our position in Fitbit.
While the overall stock market finished last week essentially unchanged, the portfolio had several outperformers.
Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the September 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
We added one new position and doubled down on another during a very good week for the portfolio.
We exited two positions last week as the portfolio and the market started off the year in the green.
- Over 800 patients from AcelRx studies supporting DSUVIA™ approval were included in the pooled safety analysis
Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACRX options chain for the new February 15th contracts and identified the following put contract of particular interest.
Despite steep declines in the broader market last week, the portfolio had several winners and was helped by our large cash position.
We added to two positions last week, as positive action in the market led the Russell 2000 to climb.
Update on DSUVIA U.S. commercialization strategy and insights from key healthcare professionals
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.